Literature DB >> 25601036

From an evolutionary perspective, all 'new' antimicrobial targets are old: time to think outside the box.

Jennifer H Martin1, Albert Ferro.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25601036      PMCID： PMC4309622          DOI： 10.1111/bcp.12385

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  12 in total

1.  Meeting the societal need for new antibiotics: the challenges for the pharmaceutical industry.

Authors:  Seamus O'Brien
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

Review 2.  Sepsis: menu of new approaches replaces one therapy for all.

Authors:  Steven P Larosa
Journal:  Cleve Clin J Med       Date:  2002-01       Impact factor: 2.321

3.  A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis.

Authors:  Leonard E Weisman; Helen M Thackray; Robin H Steinhorn; William F Walsh; Herbert A Lassiter; Ramasubbareddy Dhanireddy; Beverly S Brozanski; Kristine G H Palmer; Michael S Trautman; Marilyn Escobedo; H Cody Meissner; Pontthenkandath Sasidharan; Jennifer Fretz; John F Kokai-Kun; William G Kramer; Gerald W Fischer; James J Mond
Journal:  Pediatrics       Date:  2011-07-25       Impact factor: 7.124

4.  Anti-infective use in children and pregnancy: current deficiencies and future challenges.

Authors:  Amanda Gwee; Noel Cranswick
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

5.  Antimicrobial stewardship - can we afford to do without it?

Authors:  Anna Aryee; Nicholas Price
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

6.  The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in Alaska native children: results of a clinical trial.

Authors:  Rosalyn Singleton; Jay Wenger; Joseph A Klejka; Lisa R Bulkow; Allison Thompson; Denise Sarkozy; Emilio A Emini; William C Gruber; Daniel A Scott
Journal:  Pediatr Infect Dis J       Date:  2013-03       Impact factor: 2.129

Review 7.  The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future.

Authors:  Alice Tseng; Jason Seet; Elizabeth J Phillips
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

8.  Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.

Authors:  Steven M Opal; Pierre-Francois Laterre; Bruno Francois; Steven P LaRosa; Derek C Angus; Jean-Paul Mira; Xavier Wittebole; Thierry Dugernier; Dominique Perrotin; Mark Tidswell; Luis Jauregui; Kenneth Krell; Jan Pachl; Takeshi Takahashi; Claus Peckelsen; Edward Cordasco; Chia-Sheng Chang; Sandra Oeyen; Naoki Aikawa; Tatsuya Maruyama; Roland Schein; Andre C Kalil; Marc Van Nuffelen; Melvyn Lynn; Daniel P Rossignol; Jogadish Gogate; Mary B Roberts; Janice L Wheeler; Jean-Louis Vincent
Journal:  JAMA       Date:  2013-03-20       Impact factor: 56.272

9.  Antibiotic resistance is prevalent in an isolated cave microbiome.

Authors:  Kirandeep Bhullar; Nicholas Waglechner; Andrew Pawlowski; Kalinka Koteva; Eric D Banks; Michael D Johnston; Hazel A Barton; Gerard D Wright
Journal:  PLoS One       Date:  2012-04-11       Impact factor: 3.240

10.  After TGN1412: recent developments in cytokine release assays.

Authors:  R Stebbings; D Eastwood; S Poole; R Thorpe
Journal:  J Immunotoxicol       Date:  2012-09-11       Impact factor: 3.000
View more
  1 in total

Review 1.  New Consensus Definitions for Sepsis and Septic Shock: Implications for Treatment Strategies and Drug Development?

Authors:  Michael Berry; Brijesh V Patel; Stephen J Brett
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.